skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab

ISSN: 1177-5467 ;EISSN: 1177-5483 ;DOI: 10.2147/OPTH.S81523

Full text available

Citations Cited by
  • Title:
    Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
  • Author: Lim, Laurence S ; Ng, Wei Yan ; Mathur, Ranjana ; Wong, Doric ; Wong, Edmund YM ; Yeo, Ian ; Cheung, Chui Ming Gemmy ; Lee, Shu Yen ; Wong, Tien Yin ; Papakostas, Thanos D ; Kim, Leo A
  • Subjects: aflibercept ; bevacizumab ; diabetic retinopathy ; macular edema ; ranibizumab
  • Description: Background: The purpose of this study was to determine if eyes with diabetic macular edema (DME) unresponsive to ranibizumab or bevacizumab would benefit from conversion to aflibercept. Methods: This study was conducted as a retrospective chart review of subjects with DME unresponsive to ranibizumab and/or bevacizumab and subsequently converted to aflibercept. Results: In total, 21 eyes from 19 subjects of mean age 62±15 years were included. The majority of subjects were male (63%). The median number of ranibizumab or bevacizumab injections before switching to aflibercept was six, and the median number of aflibercept injections after switching was three. Median follow-up was 5 months after the switch. Mean central foveal thickness (CFT) was 453.52±143.39 mm immediately prior to the switch. Morphologically, intraretinal cysts were present in all cases. Mean CFT after the first injection decreased significantly to 362.57±92.82 mm (Wilcoxon signed-rank test; P<0.001). At the end of follow-up, the mean CFT was 324.17±98.76 mm (P<0.001). Mean visual acuity was 0.42±0.23 logMAR just prior to the switch, 0.39±0.31 logMAR after one aflibercept injection, and 0.37±0.22 log-MAR at the end of follow-up. The final visual acuity was significantly better than visual acuity before the switch (P=0.04). Conclusion: Eyes with DME unresponsive to multiple ranibizumab/bevacizumab injections demonstrate anatomical and visual improvement on conversion to aflibercept.
  • Publisher: Dove Medical Press
  • Creation Date: 2015
  • Language: English
  • Identifier: ISSN: 1177-5467
    EISSN: 1177-5483
    DOI: 10.2147/OPTH.S81523
  • Source: GFMER Free Medical Journals
    PubMed Central
    ProQuest Central
    DOAJ Directory of Open Access Journals
    Harvard University Library DASH
    Dove Press Free
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait